Sugi Predict

Sugi Predict / Compounds / SCHEMBL557654

SCHEMBL557654

SCHEMBL557654

O=CNc1c2ccccc2nc2ccccc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM1A O60341 6/20 0.53
▸ ATM Q13315 3/20 0.50
▸ POLB P06746 5/20 0.48
▸ KMT2A Q03164 4/20 0.48
▸ RAD52 P43351 3/20 0.48
▸ ALDH1A1 P00352 6/20 0.47
▸ KDM4E B2RXH2 5/20 0.47
▸ GAA P10253 5/20 0.47
▸ GLA P06280 4/20 0.47
▸ SMN1; SMN2 Q16637 3/20 0.47
▸ HPGD P15428 2/20 0.47
▸ LMNA P02545 2/20 0.47
▸ MITF O75030 1/20 0.47
▸ TTR P02766 1/20 0.47
▸ RAB9A P51151 1/20 0.47
▸ TDP1 Q9NUW8 3/20 0.45
▸ MAPT P10636 3/20 0.45
▸ MAPK1 P28482 3/20 0.45
▸ L3MBTL1 Q9Y468 2/20 0.45
▸ NPSR1 Q6W5P4 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6860500 0.82 ALDH1A1 (0.52) KMT2AALDH1A1KDM4ELMNATDP1
SCHEMBL23630584 0.75 KDM1A (0.78) KDM1AATMPOLBKMT2ARAD52
SCHEMBL28265607 0.74 ERN1 (0.58) POLBKMT2AALDH1A1KDM4EGAA
SCHEMBL28274202 0.72 MAOA (0.42) KMT2ARAD52ALDH1A1KDM4EGAA
SCHEMBL27962998 0.72 ALDH1A1 (0.50) KMT2ARAD52ALDH1A1GAASMN1; SMN2
SCHEMBL28100413 0.72 SLC2A1 (0.46) KMT2AALDH1A1KDM4ESMN1; SMN2HPGD
SCHEMBL3042274 0.71 ERN1 (0.61) KDM1APOLBKMT2ARAD52ALDH1A1
SCHEMBL5410460 0.71 KDM1A (0.66) KDM1AATMPOLBKMT2ARAD52
SCHEMBL17154431 0.71 KDM1A (0.59) KDM1AATMPOLBKMT2ARAD52
SCHEMBL13912471 0.71 KDM1A (0.59) KDM1AATMPOLBKMT2ARAD52

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120035320-A1 POLYACRIDINE NUCLEIC ACID DELIVERY PEPTIDE COMPLEXES UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) 2012-02-09 — — US claimed
CN-110494752-A With the method for early stage biomarker ubiquitin carboxy terminal hydrolase-l 1 assisted diagnosis measurement people experimenter traumatic brain injury degree ABBOTT LAB 2019-11-22 — — CN disclosed
CN-110383068-A Improved methods for assessing UCH-L1 status in patient samples 雅培实验室 2019-10-25 — — CN disclosed
CN-110240653-A Anti- GP73 monoclonal antibody and the method for obtaining anti-GP73 monoclonal antibody 雅培制药有限公司 2019-09-17 — — CN disclosed
CN-110249226-A Improved method for assessing GFAP status in patient samples 雅培实验室 2019-09-17 — — CN disclosed
CN-105189549-B anti-GP 73 monoclonal antibody and method for obtaining anti-GP 73 monoclonal antibody 雅培制药有限公司 2019-06-28 — — CN disclosed
CN-105228649-B HCV antigen-antibody combination assays and methods and compositions for use therein 雅培制药有限公司 2019-01-18 — — CN disclosed
CN-108603882-A Use of laminin 2 for diagnosis of hepatocellular carcinoma and pancreatic cancer 雅培日本有限公司 2018-09-28 — — CN disclosed
CN-108469523-A The prognosis of cancer and diagnostic method 雅培日本有限公司 2018-08-31 — — CN disclosed
CN-108291233-A composition and method for protein detection 先正达参股股份有限公司 2018-07-17 — — CN disclosed
CN-104755935-A Methods for prognosis and diagnosis of cancer ABBOTT JAPAN CO LTD 2015-07-01 — — CN disclosed
CN-104303060-A Method for selecting or identifying subject for v1B antagonist therapy ABBVIE INC 2015-01-21 — — CN disclosed
CN-103518135-A Biomarkers for coronary artery disease UNIV NEBRASKA 2014-01-15 — — CN disclosed
CN-103038638-A Methods for predicting sensitivity to treatment with a targeted tyrosine kinase inhibitor ABBVIE INC 2013-04-10 — — CN disclosed
US-8115027-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2012-02-14 — — US disclosed
US-20120035320-A1 POLYACRIDINE NUCLEIC ACID DELIVERY PEPTIDE COMPLEXES UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) 2012-02-09 — — US disclosed
US-20110039802-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2011-02-17 — — US disclosed
US-20100292500-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2010-11-18 — — US disclosed
US-7781461-B2 NPY Y5 antagonist KAWANISHI YASUYUKI 2010-08-24 — — US disclosed
US-7265130-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2007-09-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120035320-A1 POLYACRIDINE NUCLEIC ACID DELIVERY PEPTIDE COMPLEXES NUP205, PABPC1, SARNP KDM1A 4499/4885ATM 2466/4885POLB 102/4885
US-20100292500-A1 NPY Y5 ANTAGONIST NPY5R, NPY1R, NPY2R KDM1A 1545/4885ATM 4831/4885POLB 4751/4885
US-20110039802-A1 NPY Y5 ANTAGONIST NPY5R, NPY1R, NPY2R KDM1A 1580/4885ATM 4834/4885POLB 4721/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.